COMPANY
- Home
- Company | History
- Present ~ 2010
- 2002 ~2009
-
2020
- Cellgram-AKI, an allogeneic mesenchymal stem cell therapy for the treatment of COVID-19, approved for use in treatment (KFDA)
- Patent registration : Method for Producing Monocyte Derived From Bone Marrow
-
2019
- Patent registration : Composition for Inducing Maturation of Next-Generation Dendritic Cell Comprising Ginsenoside Rg3 and Method for Producing Next-Generation Dendritic Cell Using the Same
-
2018
- Completed construction of a new plant in Ulsan for Biochemical Division
- Launched a new cosmetics line 'Cellgram-S'
-
2017
- 1st Clinical trial for alcoholic cirrhosis treatment using stem cells (Cellgram-Liver), approved in US FDA
- Applied for the approval of the domestic conditional permit for alcoholic cirrhosis treatment using stem cells (Cellgram-Liver)
- Launched a new cosmetics line ‘Celbyten (Cx10)’
- Awarded ‘2017 Health and Medical Technology Contributor' from the Minister of Health and Welfare
-
2016
- Selected as 'Innovative Pharmaceutical Company' by the Ministry of Health and Welfare
- Selected as 'Global Leading Company' by Korea Industrial Complex Corporation
- Awarded ‘the 2016 Venture Activation Award’, by the Minister of Trade, Industry and Energy Award
- Hyun-soo Kim, CEO established a stem cell medical institution 'Kim Hyun-soo Clinic'
-
2015
- Launching the new Stem cell media cosmetic line ‘Stem-C’
-
2014
- Changed representative system (Kim Seong Rae selected as an representative)
- Selected as ‘A Promising Export SME' (Small and Medium Business Administration)
- Clinical study for commercialization of critical lower limb ischemia using stem cell(Cellgram-CLI) (IND-I phase) approved – MFDS(KFDA)
- Clinical study for commercialization of impotence drug(Cellgram-ED) (IND-I phase) approved – MFDS(KFDA)
- Organic phosphorus flame retardant and manufacturing method thereof
-
2013
- Small scale merger of IDB- Chem Co., Ltd.
- Obtained SFDA hygien certificate of China
- Commenced OEM business of cosmetics containing stem cell culture media
-
2012
- Acquisition of IDB- Chem Co., Ltd. (forerunner of Biochemical Business Division)
- Clinical study for commercialization of alcoholic cirrhosis drug using stem cell(Cellgram-Liver) (IND-III phase) approved – KFDA
-
2011
- Changed its name to ‘Pharmicell Co., Ltd.'
- The world first stem cell drug, ‘Hearticellgram-AMI’ approved - KFDA
- Won grand prize at Public Health Industry Technology Award in the area of industrial development (Ministry of Health and Welfare)
-
2010
- Completed Seongnam GMP factory
-
2009
- Commenced stem cell culture media cosmetic products
-
2008
- Registered patent : USA patent with dendritic cell production technology for anticancer immune treatment (No.7390658)
-
2007
- Selected as ‘The World Best Next Generation Product Corporation' (Ministry of Knowledge and Economy)
- Clinical study for commercialization of spinal cord injury drug using stem cell (IND-II/III phase) approved - KFDA
- Registered patent: nerve cell production technology, USA (No. 7229827), Japan(No. 3976190), Australia(No. 2003273118)
-
2006
- Clinical study for commercialization of acute myocardial infarction drug, ‘Hearticellgram-AMI’, using stem cell(IND-II/III phase), approved – KFDA
-
2005
- Won the grand prize at Public Health Industry Technology Award in the area of research(Ministry of Health and Welfare)
- Clinical study for commercialization of acute cerebral infarction drug using stem cell (IND-III phase) approved - KFDA
-
2004
- Commenced adult stem cell banking business
- Registered patent: high-functional dendritic cell production technology for anticancer immune treatment using stem cell (No. 0429140)
- Registered patent: nerve cell production technology for treatment of brain/nervous system disease using stem cell (No. 0449141)
-
2003
- Opened cell treatment center in Wonju Severance Christian Hospital
-
2002
- Established the company